FCFoteini Chouliara

Foteini Chouliara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Foteini Chouliara has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Areti Kourti

    Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece

    3 shared publications
  • Ioannis Kalogiannidis

    Third Department of Obstetrics and Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece

    3 shared publications
  • Kali Makedou

    Laboratory of Biochemistry, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece

    3 shared publications
  • Elisavet Georgiou

    Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece

    2 shared publications
  • Paraskevi Karioti

    3rd Department of Obstetrics and Gynecology, Hippokratio General Hospital of Thessaloniki, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece

    2 shared publications
  • Aikaterini Sidera

    Third Department of Obstetrics and Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 541-24 Thessaloniki, Greece

    1 shared publication

Latest Publications

  • Open Access

    Oxidative Stress and Its Molecular Effectors in Uterine Smooth Muscle Tumors: Bridging Epigenetic Regulation and Glycoprotein Biomarkers

    by Areti Kourti, Paraskevi Karioti, Foteini Chouliara, Elisavet Georgiou, Kali Makedou, Ioannis Kalogiannidis

    Background: Uterine smooth muscle tumors present a diverse clinical spectrum, ranging from ubiquitous benign leiomyomas to highly lethal uterine leiomyosarcomas (uLMSs). The preoperative differentiation of these entities, alongside the intermediate smooth muscle tumors of uncertain malignant potential (STUMP), remains an unresolved clinical challenge. Methods: This comprehensive review synthesizes the current literature on the pathogenesis of uterine smooth muscle tumors, focusing on the role of oxidative stress and its downstream molecular effectors. We evaluate the interplay between oxidative stress markers, epigenetic regulation via microRNAs (miRNAs), and circulating glycoproteins. Results: Increased oxidative stress is a hallmark associated with uLMS, characterized by altered antioxidant enzyme activity and elevated lipid peroxidation products such as malondialdehyde (MDA). This oxidative burden is associated with DNA damage and profound genomic instability, participating in the evolution of the malignant phenotype. Concurrently, the stressed tumor microenvironment exhibits significant epigenetic deregulation. Tumor-suppressive miRNAs (e.g., the miR-29 and miR-200 families) are downregulated, while oncogenic miRNAs (e.g., miR-21) are upregulated, promoting survival and proliferation pathways. Furthermore, galectin-1, a glycoprotein responsive to microenvironmental stress, is elevated in the serum of uLMS and STUMP patients, demonstrating high specificity in investigated cohorts, though limited sensitivity (47%), whereas mucin-1 (MUC1) shows no significant diagnostic utility. Conclusions: Oxidative stress is strongly associated with the genomic instability and molecular derangements observed in uterine sarcomas. Integrating oxidative stress indicators with specific miRNA signatures and galectin-1 levels could potentially yield robust, non-invasive diagnostic panels. However, prospective validation in large, independent cohorts is strictly required before these markers can be implemented to improve preoperative risk stratification and guide targeted therapeutic interventions.

  • Open Access

    Oxidative Stress and Its Molecular Effectors in Uterine Smooth Muscle Tumors: Bridging Epigenetic Regulation and Glycoprotein Biomarkers

    by Areti Kourti, Paraskevi Karioti, Foteini Chouliara, Elisavet Georgiou, Kali Makedou, Ioannis Kalogiannidis

    Background: Uterine smooth muscle tumors present a diverse clinical spectrum, ranging from ubiquitous benign leiomyomas to highly lethal uterine leiomyosarcomas (uLMS). The preoperative differentiation of these entities, alongside the intermediate smooth muscle tumors of uncertain malignant potential (STUMP), remains an unresolved clinical challenge. Methods: This comprehensive review synthesizes the current literature on the pathogenesis of uterine smooth muscle tumors, strictly focusing on the role of oxidative stress and its downstream molecular effectors. We evaluate the interplay between oxidative stress markers, epigenetic regulation via microRNAs (miRNAs), and circulating glycoproteins. Results: Increased oxidative stress is a hallmark of uLMS, characterized by altered antioxidant enzyme activity and elevated lipid peroxidation products such as malondialdehyde (MDA). This oxidative burden drives DNA damage and profound genomic instability, facilitating the evolution of the malignant phenotype. Concurrently, the stressed tumor microenvironment exhibits significant epigenetic deregulation. Tumor-suppressive miRNAs (e.g., the miR-29 and miR-200 families) are downregulated, while oncogenic miRNAs (e.g., miR-21) are upregulated, hyperactivating survival and proliferation pathways. Furthermore, galectin-1, a glycoprotein responsive to microenvironmental stress, is significantly elevated in the serum of uLMS and STUMP patients, demonstrating a high specificity (100%) for malignancy, whereas mucin-1 (MUC1) shows no significant diagnostic utility. Conclusions: Oxidative stress serves as a central catalyst for the genomic instability and molecular derangements observed in uterine sarcomas. Integrating oxidative stress indicators with specific miRNA signatures and galectin-1 levels could yield robust, non-invasive diagnostic panels, ultimately improving preoperative risk stratification and guiding targeted therapeutic interventions.

  • Open Access

    The Impact of Osteopontin and Galectin-7 on the Preoperative Diagnosis of Ovarian Tumors: A Case–Control Study

    by Foteini Chouliara, Aikaterini Sidera, Ioannis Tsakiridis, Areti Kourti, Georgios Michos, Evangelos Papanikolaou, Themistoklis Dagklis, Apostolos Mamopoulos, Kali Makedou, Ioannis Kalogiannidis

    Background/Objectives: Accurate preoperative discrimination between women with ovarian pathology and healthy controls, as well as between benign and malignant ovarian tumors, remains challenging. This study aimed to evaluate the usefulness of osteopontin and galectin-7 on the diagnosis of ovarian tumors. Methods: This prospective single-center case–control study was conducted at the Third Department of Obstetrics & Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece, between 2018 and 2024. Preoperative serum levels of osteopontin, galectin-7, and established tumor markers (CA-125, CA19-9, CA15-3, CEA, AFP) were analyzed. Biomarker distributions were compared using non-parametric tests. Associations with clinical variables were explored using correlation analyses. Logistic regression and receiver operating characteristic (ROC) curve analyses were performed to assess diagnostic performance. Results: The study population included 116 women: 52 healthy controls, 45 patients with benign ovarian tumors, and 19 patients with malignant ovarian tumors. Serum osteopontin and galectin-7 levels did not differ significantly between control and study group (p = 0.562 and p = 0.138, respectively), nor between benign and malignant tumors (p = 0.784 and p = 0.140, respectively). Osteopontin showed no discriminatory ability (AUC = 0.47), while galectin-7 demonstrated weak discrimination (AUC = 0.63). A combined model yielded modest improvement (AUC = 0.69), remaining below clinically meaningful thresholds. CA-125 was the only biomarker significantly associated with malignancy (OR = 1.03, p = 0.038). Galectin-7 levels were higher in premenopausal women and inversely correlated with age, suggesting demographic rather than malignant influence. Conclusions: Despite strong biological relevance, circulating osteopontin and galectin-7 did not provide meaningful diagnostic discrimination between women with ovarian pathology and healthy controls or between benign and malignant ovarian tumors. CA-125 remained the most informative serum marker in this setting. Future efforts should focus on multi-marker strategies integrated with imaging and clinical assessment.